(Q45900548)

English

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.

scientific article published on 24 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

1 reference

based on heuristic

inferred from title

author name string

Jenny M Whitworth

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Kellie S Matthews

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Kimberly A Shipman

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

T Michael Numnum

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

James E Kendrick

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Larry C Kilgore

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

J Michael Straughn

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

language of work or name

0 references

publication date

24 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

112

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

601-604

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Same-day pegfilgrastim and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.025

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.10.025

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19110303

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45900548&oldid=1727146862"